Last winter, I donated my kidney to a stranger. As a nephrologist, I see people every day who need a gently used kidney, and ...

The Company currently has a pipeline of programmes in development including the lead asset for treatment of IgA Nephropathy (IgAN) and other complement mediated kidney disease. The Company also has ...

The company also delivered a 60 basis-point increase in its gross margin, delivering a gross profit of $1.4 billion for the ...

My illness previously dictated how I planned my days, years and entire sense of possibility – pregnancy has disrupted that ...

A dual algorithm claims analysis revealed the rare burden of primary IgA nephropathy in Germany and underscored the need for precise diagnostic coding.

The 33-year-old suffered from painful migraines and then suddenly collapsed. Doctors determined he was in kidney failure and will likely need a kidney transplant.

Game Changers in Nephrology' was the theme of the 62nd European Renal Association (ERA) Congress, held in Vienna, ...

Witnessing her son's ongoing pain and deteriorating health, his mother took the brave decision to donate one of her kidneys.

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued ...

The iBox Scoring System is a novel composite biomarker endpoint predictive of long-term graft survival after kidney ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

Otsuka and Vera Therapeutics have both presented new data on drug candidates for IgA nephropathy (IgAN), striving to join a market which is becoming increasingly crowded.